AG
BBC icon

Advisor Group’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Advisor Group’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$71K Buy
+1,860
New +$55.3K ﹤0.01% 3182
2017
Q3 		– Sell
-100
Closed -$2K – 4832
2017
Q2 		$2K Buy
+100
New +$2.24K ﹤0.01% 4492

Other funds holding BBC

Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
AWCI
Alpine Woods Capital Investors Purchase, New York $417M AUM 26.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
RWB
RMR Wealth Builders Montclair, New Jersey $1.27B AUM 19.16% 1-Year Est. Return

Advisor Group's BBC Position: Q4 2019 in Review

Advisor Group opened a new position in Virtus Biotech Clinical Trials ETF (BBC) in Q4 2019: 1,860 shares worth $71K. The stake represents ﹤0.01% of the portfolio and ranks #3182 among its holdings. This is a return to the name: Advisor Group previously reported a position in BBC as recently as Q2 2017.

Advisor Group first reported a position in BBC in Q2 2017 and has held it in 2 quarters since. 16 funds tracked by Wall St. Rank hold BBC as of Q4 2019.

  • Advisor Group held 1,860 shares of Virtus Biotech Clinical Trials ETF worth $71K as of Q4 2019.
  • Virtus Biotech Clinical Trials ETF was a new Advisor Group position in Q4 2019.
  • Virtus Biotech Clinical Trials ETF made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #3182 holding.
  • Advisor Group first reported a position in Virtus Biotech Clinical Trials ETF in Q2 2017 and has held it in 2 quarters since.
  • 16 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.